Prepared by R.R. Donnelley Financial -- Form 8-K Dated September 24, 2002
 
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
FORM 8-K
 
Current Report Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported):    September 24, 2002
 
SYNBIOTICS CORPORATION
(Exact name of registrant as specified in its charter)
 
Commission file number 0-11303
 
California
  
95-3737816
(State or other jurisdiction
of incorporation )
  
(I.R.S. Employer
Identification No.)
11011 Via Frontera
San Diego, California
  
92127
(Address of principal executive offices)
  
(Zip Code)
 
Registrant’s telephone number, including area code: (858) 451-3771
 

 
Item 5.    Other Events
 
On September 24, 2002, we announced that Paul A. Rosinack, President and Chief Executive Officer and member of the Board of Directors, and Michael K. Green, Sr. Vice President and Chief Financial Officer, have resigned. We also announced that Keith A. Butler, our Corporate Controller, has been appointed to Vice President and Chief Financial Officer, and that a subcommittee of the Board of Directors will assume executive duties until a new Chief Executive Officer is selected.
 
Item 7.    Financial Statements, Pro Forma Financial Information and Exhibits
 
 
a)
 
Financial statements of businesses acquired
 
Not applicable.
 
 
b)
 
Pro forma financial information
 
Not applicable.
 
 
c)
 
Exhibits
 
99
   
Press release dated September 24, 2002 entitled “Synbiotics Announces Management Changes”.
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
SYNBIOTICS CORPORATION
/s/    KEITH A. BUTLER        
Keith A. Butler
Vice President—Finance and Chief Financial Officer
Date: October 2, 2002
 

-1-

 
EXHIBIT INDEX
 
Exhibit No.
   
Exhibit
99
   
Press release dated September 24, 2002 entitled “Synbiotics Announces Management Changes”.

 
SECURITIES AND EXCHANGE COMMISSION
 
WASHINGTON, D.C.
 
EXHIBITS
 
TO
 
FORM 8-K
 
UNDER
 
SECURITIES EXCHANGE ACT OF 1934
 
SYNBIOTICS CORPORATION